Tags

Type your tag names separated by a space and hit enter

Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.
J Chin Med Assoc. 2021 01 01; 84(1):9-13.JC

Abstract

The pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has brought an unprecedented impact upon the global economy and public health. Although the SARS-CoV-2 virology has been gradually investigated, measures to combat this new threat in public health are still absent. To date, no certificated drug or vaccine has been developed for the treatment or prevention of coronavirus disease Extensive researches and international coordination has been conducted to rapidly develop novel vaccines against SARS-CoV-2 pandemic. Several major breakthroughs have been made through the identification of the genetic sequence and structural/non-structural proteins of SARS-CoV-2, which enabled the development of RNA-, DNA-based vaccines, subunit vaccines, and attenuated viral vaccines. In this review article, we present an overview of the recent advances of SARS-CoV-2 vaccines and the challenges that may be encountered in the development process, highlighting the advantages and disadvantages of these approaches that may help in effectively countering COVID-19.

Authors+Show Affiliations

Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Institute of Preventive Medicine, National Defense Medical Center, Taipei, Taiwan, ROC.School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC. Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC. Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC. Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC. School of Medicine, National Yang-Ming Medical University, Taipei, Taiwan, ROC.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

33186212

Citation

Liu, Cheng-Hsuan, et al. "Highlight of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Development Against COVID-19 Pandemic." Journal of the Chinese Medical Association : JCMA, vol. 84, no. 1, 2021, pp. 9-13.
Liu CH, Huang HY, Tu YF, et al. Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic. J Chin Med Assoc. 2021;84(1):9-13.
Liu, C. H., Huang, H. Y., Tu, Y. F., Lai, W. Y., Wang, C. L., Sun, J. R., Chien, Y., Lin, T. W., Lin, Y. Y., Chien, C. S., Huang, C. H., Chen, Y. M., Huang, P. I., Wang, F. D., & Yang, Y. P. (2021). Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic. Journal of the Chinese Medical Association : JCMA, 84(1), 9-13. https://doi.org/10.1097/JCMA.0000000000000461
Liu CH, et al. Highlight of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Development Against COVID-19 Pandemic. J Chin Med Assoc. 2021 01 1;84(1):9-13. PubMed PMID: 33186212.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic. AU - Liu,Cheng-Hsuan, AU - Huang,Hsuan-Yang, AU - Tu,Yung-Fang, AU - Lai,Wei-Yi, AU - Wang,Chia-Lin, AU - Sun,Jun-Ren, AU - Chien,Yueh, AU - Lin,Tzu-Wei, AU - Lin,Yi-Ying, AU - Chien,Chian-Shiu, AU - Huang,Chih-Heng, AU - Chen,Yuh-Min, AU - Huang,Pin-I, AU - Wang,Fu-Der, AU - Yang,Yi-Ping, PY - 2020/11/14/pubmed PY - 2021/1/27/medline PY - 2020/11/13/entrez SP - 9 EP - 13 JF - Journal of the Chinese Medical Association : JCMA JO - J Chin Med Assoc VL - 84 IS - 1 N2 - The pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has brought an unprecedented impact upon the global economy and public health. Although the SARS-CoV-2 virology has been gradually investigated, measures to combat this new threat in public health are still absent. To date, no certificated drug or vaccine has been developed for the treatment or prevention of coronavirus disease Extensive researches and international coordination has been conducted to rapidly develop novel vaccines against SARS-CoV-2 pandemic. Several major breakthroughs have been made through the identification of the genetic sequence and structural/non-structural proteins of SARS-CoV-2, which enabled the development of RNA-, DNA-based vaccines, subunit vaccines, and attenuated viral vaccines. In this review article, we present an overview of the recent advances of SARS-CoV-2 vaccines and the challenges that may be encountered in the development process, highlighting the advantages and disadvantages of these approaches that may help in effectively countering COVID-19. SN - 1728-7731 UR - https://www.unboundmedicine.com/medline/citation/33186212/Highlight_of_severe_acute_respiratory_syndrome_coronavirus_2_vaccine_development_against_COVID_19_pandemic_ L2 - https://doi.org/10.1097/JCMA.0000000000000461 DB - PRIME DP - Unbound Medicine ER -